Filing Flows › Arcutis Biotherapeutics (ARQT) › Q3 2025
Arcutis Biotherapeutics (ARQT) Q3 2025 earnings results (third quarter 2025)
10-Q filed Oct 28, 2025
Arcutis Biotherapeutics (ARQT) reported revenue of $99.2M for the third quarter 2025 (Q3 2025), +122% from a year earlier and +22% from the quarter before. Operating margin was 8.6%, net earnings $7.4M (7.5% of revenue).
Arcutis Biotherapeutics, Q3 2025: revenue $99.2M (+122% year over year), operating margin 8.6%, net earnings $7.4M, operating cash flow −$1.8M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $99.2M | +22% | +122% |
| Operating profit | $8.5M | — | — |
| Net earnings | $7.4M | — | — |
| Operating cash flow | −$1.8M | -641% | — |
What changed
Revenue was $99.2M in Q3 2025, up 122% year over year and up 22% from the previous quarter. ZORYVE foam was the largest line at 50% of revenue. ZORYVE foam added $29.5M year over year (up 146%), 54% of the total change.
Operating profit was $8.5M, a 8.6% margin (up 95.9 points year over year). Total costs grew 8% against revenue growth of 122%. The fastest-growing cost line was Cost of revenue (+58%). Net earnings were $7.4M. The effective tax rate was 1.1%.
Operating cash flow was −$1.8M. Non-cash charges added back $10.0M of share-based compensation. Working capital and other items used $19.2M.
Questions
What was Arcutis Biotherapeutics' revenue in the third quarter 2025?
Arcutis Biotherapeutics (ARQT) reported revenue of $99.2M for the third quarter 2025 (Q3 2025), +122% from a year earlier and +22% from the quarter before.
Was Arcutis Biotherapeutics profitable in the third quarter 2025?
Operating profit was $8.5M (8.6% of revenue) and net earnings $7.4M.